Search

Certain polybrominated diphenyl ethers (PBDEs) have been banned for years, however, they still possess the potential to harm marine cetaceans. In this study, 56 East Asian finless porpoises (EAFPs) collected from three locations of the East China Sea between 2009 and 2011, were analyzed to determine the presence of typical PBDE congeners. Among all the samples, BDE47 was the main congener, constituting ∼48.3 % of the ΣPBDEs. Significant variations (p < 0.01) in PBDE abundance were observed among different regions (Pingtan: 172.8 ng/g, Lvsi: 61.2 ng/g and Ningbo: 32.9 ng/g). In addition, there was a significant positive correlation between PBDE abundance and male body length. The general ΣPBDEs concentration of this population was lower compared to other populations and cetaceans. Although combined risk assessments indicated a low risk to porpoise health, long-term surveillance is essential as PBDEs are not completely banned. [Display omitted] • It is the first report of PBDEs in East Asian finless porpoise from the East China Sea, China. • BDE47 was the highest concentrated congener detected in this study. • The contaminant levels of PBDEs showed significant regional variations in distribution. • Combined risk assessments suggested that porpoises had a low health risk from PBDEs. [ABSTRACT FROM AUTHOR]

• The quantity, quality and developmental potential of the embryos were significantly lower and significantly worse IVF and pregnancy outcomes, including lower implantation rate, clinical pregnancy rate and take-home baby rate in women with positive anti-SSA/SSB antibodies. • Immune factors may be responsible for the poor embryos and adverse IVF outcomes. Therefore, patients may benefit from therapeutic regimens targeting immunity. Anti-Ro/SSA and/or anti-La/SSB antibodies (anti-SSA/SSB) were reported to increase the risk of recurrent pregnancy loss. However, the effects of anti-SSA/SSB antibodies on in-vitro fertilization (IVF) and pregnancy outcomes were still unclear. The purpose of the study was to determine whether anti-SSA/SSB antibodies were detrimental to IVF and pregnancy outcomes. This study included 55 anti-SSA/SSB antibodies-positive women and 61 anti-SSA/SSB antibodies-negative control women receiving gonadotropin-releasing hormone (GnRH) agonist long protocol (n = 30 and 39, respectively) or GnRH antagonist protocol (n = 25 and 22, respectively) for in-vitro fertilization and embryo transfer (IVF-ET). The impact of anti-SSA/SSB antibodies on immune-related indicators, fertilization, embryo development and pregnancy outcomes were analyzed. With either GnRH agonist or antagonist protocol, women with anti-SSA/SSB had higher levels of peripheral blood cytokines, including TNF-α and IL-17A, lower levels of peripheral blood Th and NK cells, and poor IVF outcomes, including lower number of retrieved oocytes and embryos, lower M II oocytes rate, blastocyst formation rate, and perfect and available embryo rates. Moreover, clinical pregnancy rate, implantation rate, take-home baby rate, and birth weight were significantly lower in the study group as compared with those of the control group. In conclusion, women with anti-SSA/SSB are associated with adverse IVF and pregnancy outcomes. Screening for these antibodies and proper counselling of couples undergoing IVF-ET should be considered. Underlying immunopathology associated with SSA/SSB antibodies and reproduction should be explored further. [ABSTRACT FROM AUTHOR]